ORPHALAN
Current Employees Featured
Official Site Inspections
http://www.orphalan.com
- Host name: 104.248.174.66
- IP address: 104.248.174.66
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "Orphalan"
Orphalan - Crunchbase Company Profile & Funding
Orphalan is located in Paris, Ile-de-France, France. Who are Orphalan 's competitors? Alternatives and possible competitors to Orphalan may include Peroxitech Therapeutics , Saphtx , and Kisbee Therapeutics .See details»
Orphalan - LinkedIn
Orphalan | 3,731 followers on LinkedIn. At Orphalan we strive to develop rare disease treatments to improve patients lives. | Transforming Rare Disease Treatment At Orphalan we identify, develop ...See details»
Maintain Copper Balance with Cuvrior
This video features Dr Amanda Cheung, Hepatologist; Rhonda Rowland from the Wilson Disease Association; Dr Naseem Amin, Orphalan CEO; and Mandy, CUVRIOR's Patient Ambassador, discussing Wilson Disease, its impact, and …See details»
Orphalan Company Profile 2024: Valuation, Funding
Orphalan General Information Description. Developer of treatments for rare diseases intended to improve the lives of patients. The company uses a global network of experts including scientists, academic institutions, and companies …See details»
Orphalan - Products, Competitors, Financials, Employees, …
Rhonda Rowland, VP of the WDA, discusses the evolution of treatment options and the organization's role in fostering partnerships between patients, physicians, and the …See details»
Orphalan announces US commercial launch of Cuvrior™ for the
Apr 20, 2023 Orphalan is a pioneering, international orphan drug development and commercialization company. Founded in 2011, the company develops and delivers innovative …See details»
Orphalan announces FDA approval of Cuvrior™ for the treatment …
Orphalan. Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 …See details»
Orphalan announces US commercial launch of Cuvrior™ for the …
Apr 20, 2023 Orphalan. Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine — Oral …See details»
Orphalan announces enrolment of the first five patients in the ...
Paris, France [26 July], 2022 -- Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of …See details»
Orphalan announces data from secondary analyses of the
Jun 22, 2022 Orphalan announces data from secondary analyses of the CHELATE trial for maintenance p ... Orphalan was founded in 2011 and has launched Cuprior® across Europe …See details»
Orphalan strengthens its management team with two key
Orphalan was founded in 2011 and has launched Cuprior™ across Europe with its own commercial organisation. For more information, visit www.orphalan.health and follow us on …See details»
Behind The Mystery Unveils Treatment in Wilson Disease with …
Aug 19, 2024 Orphalan is an international orphan drug development and commercialization company headquartered in Paris. Founded in 2011, the company develops innovative …See details»
FDA Approves Cuvrior (trientine tetrahydrochloride) for the …
May 2, 2022 About Orphalan. Orphalan is an international orphan drug development and commercialisation company. The company delivers worldwide innovative therapies for people …See details»
Orphalan announces publication of results from the CHELATE trial …
Paris, France 30 September, 2022 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the publication …See details»
Orphalan announces FDA approval of Cuvrior™ for the treatment …
May 2, 2022 Orphalan. Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. …See details»
Behind The Mystery Unveils Treatment in Wilson Disease with …
Aug 19, 2024 CUVRIOR®, a treatment marketed by Orphalan, offers a twice-daily dosing and is a non-refrigerated option for long-term maintenance therapy for Wilson Disease. Story ContinuesSee details»
Orphalan announces enrolment of the first five patients in
Jul 26, 2022 Orphalan commercializes Cuprior®, its trientine tetrahydrochloride product for the treatment of Wilson’s disease in Europe, and is launching Cuvrior™, recently approved by the …See details»
First FDA approval for Orphalan comes for Wilson's disease
May 2, 2022 For Orphalan, the approval is a satisfying development considering its first compound—to treat spinal muscular atrophy—failed after six years in testing. RELATED: …See details»
Orphalan announces FDA acceptance for filing of New Drug
Feb 9, 2021 Orphalan was founded in 2011 and has launched Cuprior™ across Europe with its own commercial organisation. For more information, visit www.orphalan.health and follow us …See details»
Orphalan announces FDA acceptance for filing of New Drug …
Sep 2, 2021 Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA …See details»